(Q42745595)

6 November 2017

Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment (English)

1 reference

6 November 2017

0 references

1 reference

Amy C Go

1

1 reference

6 November 2017

Larry K Golightly

series ordinal

2

1 reference

6 November 2017

Gerard R Barber

series ordinal

3

1 reference

6 November 2017

Michelle A Barron

series ordinal

4

1 reference

6 November 2017

1 January 2010

1 reference

Drug Metabolism and Drug Interactions

6 November 2017

1 reference

6 November 2017

25

1 reference

6 November 2017

1-4

1 reference

6 November 2017

41-47

1 reference

Linezolid: a review of its use in the management of serious gram-positive infections

6 November 2017

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Benefit-risk assessment of linezolid for serious gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

In vitro susceptibilities of zygomycetes to conventional and new antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

21 January 2018

The Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Linezolid and serotonergic drug interactions: a retrospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin toxicity associated with the use of linezolid: a review of postmarketing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin Syndrome after Concomitant Treatment with Linezolid and Citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin syndrome and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Mild serotonin syndrome associated with concurrent linezolid and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin syndrome associated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Linezolid and serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin syndrome and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

A case study of delayed serotonin syndrome: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin syndrome due to co-administration of linezolid and venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Serotonin toxicity associated with concomitant use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Therapeutic challenges in the era of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

New antimicrobial molecules and new antibiotic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

New and emerging treatment of Staphylococcus aureus infections in the hospital setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Antimicrobial agents in treatment of MRSA infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

Discontinuation symptoms in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2010.001

21 January 2018

Identifiers

DOI

10.1515/DMDI.2010.001

1 reference

6 November 2017

1 reference